Page 94 - 《中国药房》2025年4期

组，中华预防医学会医院感染控制分会，中国药理学会 [19] OKADA T，MOROZUMI M，TAJIMA T，et al. Rapid
临床药理分会. 临床常用四环素类药物合理应用多学科 effectiveness of minocycline or doxycycline against
专家共识[J]. 中华医学杂志，2023，103（30）：2281-2296. macrolide-resistant Mycoplasma pneumoniae infection in
Editing Group for Multidisciplinary Expert Consensus on a 2011 outbreak among Japanese children[J]. Clin Infect
the Rational Use of Tetracyclines Commonly Used in Dis，2012，55（12）：1642-1649.
Clinical Practice，Hospital Infection Control Branch of [20] 殷勇，陈健德. 儿童大环内酯类耐药肺炎支原体肺炎诊
Chinese Preventive Medicine Association，Clinical Phar‐ 疗理念与实践[J]. 临床儿科杂志，2024，42（3）：177-181.
macology Branch of Chinese Pharmacological Society. YIN Y，CHEN J D. Diagnosis and treatment philosophy
Multidisciplinary expert consensus on the rational use of and practice of macrolide-resistant Mycoplasma pneu‐
tetracyclines commonly used in clinical practice[J]. Natl moniae pneumonia in children[J]. J Clin Pediatr，2024，42
Med J China，2023，103（30）：2281-2296. （3）：177-181.
[ 9 ] SUN L L，YE C，ZHOU Y L，et al. Meta-analysis of the [21] GAVRILOVIC S，ANDRIJEVIC A，MUJAKOVIC A，et
clinical efficacy and safety of high- and low-dose methyl‐ al. Adjunct corticosteroid treatment in patients with pneu‐
prednisolone in the treatment of children with severe monia：a precision medicine approach[J]. Bosn J Basic
Mycoplasma pneumoniae pneumonia[J]. Pediatr Infect Med Sci，2019，19（4）：315-320.
Dis J，2020，39（3）：177-183. [22] 王克华，郭琼杰，王娜 . 基于美国 FDA 不良事件报告系
[10] BAE E，KIM Y J，KANG H M，et al. Macrolide versus 统数据库的多西环素儿童相关不良事件风险信号挖掘
non-macrolide in combination with steroids for the treat‐ [J]. 药物不良反应杂志，2024，26（3）：157-161.
ment of lobar or segmental Mycoplasma pneumoniae WANG K H，GUO Q J，WANG N. Signal mining of risk
pneumonia unresponsive to initial macrolide monotherapy of doxycycline-related adverse events in children based on
[J]. Antibiotics，2022，11（9）：1233. US FDA adverse event reporting system database[J].
[11] NARANJO C A，BUSTO U，SELLERS E M，et al. A Adverse Drug React J，2024，26（3）：157-161.
method for estimating the probability of adverse drug reac‐ [23] 陈龙，陈高艳，丁楠楠. 基于FAERS数据库对8岁以下儿
tions[J]. Clin Pharmacol Ther，1981，30（2）：239-245. 童使用四环素类药物的 ADR 信号挖掘[J]. 中南药学，
[12] FREITES-MARTINEZ A， SANTANA N， ARIAS- 2024，22（10）：2819-2825.
SANTIAGO S，et al. Using the common terminology CHEN L，CHEN G Y，DING N N. Data mining of tetracy‐
criteria for adverse events（CTCAE - version 5.0）to evaluate clines ADR signals in children under 8 based on FAERS
the severity of adverse events of anticancer therapies[J]. database[J]. Cent South Pharm，2024，22（10）：2819-2825.
Actas Dermosifiliogr，2021，112（1）：90-92. [24] DAĞ M S，ÖZTÜRK Z A，AKıN I，et al. Drug-induced
[13] LEE H，YUN K W，LEE H J，et al. Antimicrobial therapy esophageal ulcers：case series and the review of the litera‐
of macrolide-resistant Mycoplasma pneumoniae pneu- ture[J]. Turk J Gastroenterol，2014，25（2）：180-184.
monia in children[J]. Expert Rev Anti Infect Ther，2018， [25] 王璐，曾露，魏安华 . 基于美国 FDA 不良事件报告系统
16（1）：23-34. 数据库的不同年龄段人群多西环素风险信号分析[J].中
[14] GORDON O，OSTER Y，MICHAEL-GAYEGO A，et al. 国临床药学杂志，2024，33（7）：509-514.
The clinical presentation of pediatric Mycoplasma pneu‐ WANG L，ZENG L，WEI A H. Analysis of risk signals of
moniae infections：a single center cohort[J]. Pediatr Infect doxycycline in different age groups based on the FDA
Dis J，2019，38（7）：698-705. adverse event reporting system database[J]. Chin J Clin
[15] KAWAI Y，MIYASHITA N，KUBO M，et al. Therapeutic Pharm，2024，33（7）：509-514.
efficacy of macrolides，minocycline，and tosufloxacin against [26] BLAKELY K M，DRUCKER A M，ROSEN C F. Drug-
macrolide-resistant Mycoplasma pneumoniae pneumonia induced photosensitivity：an update：culprit drugs，preven‐
in pediatric patients[J]. Antimicrob Agents Chemother， tion and management[J]. Drug Saf，2019，42（7）：827-847.
2013，57（5）：2252-2258. [27] LAYTON A M，CUNLIFFE W J. Phototoxic eruptions
[16] CHEONG K N，CHIU S S，CHAN B W，et al. Severe due to doxycycline：a dose-related phenomenon[J]. Clin
macrolide-resistant Mycoplasma pneumoniae pneumonia Exp Dermatol，1993，18（5）：425-427.
associated with macrolide failure[J]. Wei Mian Yu Gan [28] RAVINDRA D，HUANG G，HALLETT K，et al.
Ran Za Zhi，2016，49（1）：127-130. Antibiotic exposure and dental health：a systematic review
[17] CHEN Y，ZHANG Y，TANG Q N，et al. Efficacy of doxy‐ [J]. Pediatrics，2023，152（1）：e2023061350.
cycline therapy for macrolide-resistant Mycoplasma pneu‐ [29] WEI C Y，LIU Y，JIANG A D，et al. A pharmacovigilance
moniae pneumonia in children at different periods[J]. Ital study of the association between tetracyclines and hepato‐
J Pediatr，2024，50（1）：38. toxicity based on Food and Drug Administration adverse
[18] LEE H，CHOI Y Y，SOHN Y J，et al. Clinical efficacy of event reporting system data[J]. Int J Clin Pharm，2022，44
doxycycline for treatment of macrolide-resistant Myco‐ （3）：709-716.
plasma pneumoniae pneumonia in children[J]. Antibiotics， （收稿日期：2024-09-09 修回日期：2024-12-27）
2021，10（2）：192. （编辑：陈 宏）

· 468 · China Pharmacy 2025 Vol. 36 No. 4 中国药房 2025年第36卷第4期